A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 21, 2020

Primary Completion Date

July 9, 2021

Study Completion Date

July 9, 2021

Conditions

Hepatic ImpairmentHealthy Participants

Interventions

DRUG

PF-06835919 25 mg

PF-06835919 in 25 mg oral tablet will be administered on Day 1

Trial Locations (3)

Summit Clinical Research, s.r.o.,, Bratislava

Pfizer Clinical Research Unit - Brussels, Brussels

Pharmaceutical Research Associates CZ, s.r.o., Prague